News« Back to News
Gaithersburg, M.D. – May 29, 2015 - The 2015 USP Compliance Study registration is now available online and will remain open through June 30th this summer. With the landscape of sterile compounding changing quickly, now is the time to make sure you have identified your operational risks associated with aseptic compounding and that your facility has conducted a comprehensive Gap Analysis so you understand your level of compliance with the USP Chapter . Led by Eric Kastango, Rph, MBA, FASHP, and sterile compounding expert and Study Co-Director, Kate Douglass, MS, RN, APN, C, CRNI, this study continues to be the largest and most comprehensive study of compliance in the United States.
The information obtained from this year’s Study will be very valuable to the compounding pharmacy industry. These results assist in benchmarking industry progress and identifying where additional resources and focus are required to continue to improve sterile compounding practice and safety. The results of this Study will be published this fall in Pharmacy Purchasing & Products Magazine.
The 2015 USP Compliance Study uses a sophisticated, web-based Gap Analysis Tool that Douglass and Kastango developed and have been using for the last several years. This tool is being made available at no charge to all study participants. It should be noted that ALL INDIVIDUAL FACILITY RESULTS ARE CONFIDENTIAL – ONLY AGGREGATE DATA WILL BE USED IN THE STUDY REPORT.
In return for your participation, you will receive a highly detailed Action Plan that is automatically generated based on your responses. This Action Plan provides documentation that can be used to enhance your sterile compounding practices. The survey takes approximately 60-90 minutes to complete but does not have to be completed in one sitting. The Study Team has also provided a PDF document of all the questions to facilitate offline data collection for those who might find this useful.
Please register for the Study today: www.797study.com - Use Survey Code E797A
Your participation will help the Study Team to learn more about the successes and challenges relative to USP compliance. With that insight, it becomes easier to target additional strategies to promote best-practice sterile compounding. If you have any questions, please contact the Study Team at email@example.com.